These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7042515)

  • 1. New drug found active against lung cancers.
    Hospitals; 1982 Jun; 56(12):38. PubMed ID: 7042515
    [No Abstract]   [Full Text] [Related]  

  • 2. Ifosfamide in the treatment of bronchogenic carcinoma. A preliminary trial.
    Gandola L; Pozzi E; Tansini G
    G Ital Chemioter; 1978; 25(1):41-4. PubMed ID: 376387
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of bronchogenic cancer and lung metastases of solid tumors with ifosfamid (author's transl)].
    Hoefer H; Scheef W; Titscher R; Kokron O
    Osterr Z Onkol; 1974; (1):3-7. PubMed ID: 4619650
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of oat cell metastazing bronchial carcinoma with isofosfamide. Results of a prospective randomized study].
    Kokron O
    Osterr Z Onkol; 1974; (5-6):123-7. PubMed ID: 4377798
    [No Abstract]   [Full Text] [Related]  

  • 5. Ifosfamide: new idications-new dose strength. Limited evidence of effectiveness.
    Prescrire Int; 1998 Apr; 7(34):45-7. PubMed ID: 10183382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical experience with the cytostatic drug ifosfamide].
    Ritter S; Schröder HJ
    Med Welt; 1977 Sep; 28(35):1395-1400. PubMed ID: 70737
    [No Abstract]   [Full Text] [Related]  

  • 7. The bioavailability of oral and intravenous ifosfamide in the treatment of bronchogenic carcinoma.
    McNiel NO; Morgan LR
    Int J Clin Pharmacol Ther Toxicol; 1981 Nov; 19(11):490-3. PubMed ID: 7298241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide in non-small cell lung cancer.
    Johnson DH
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):7-10. PubMed ID: 8677453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experience with fractionate massive-dose Ifosfamid therapy of generalized malignant tumors].
    Hoefer-Janker H; Scheef W; Günther U; Hüls W
    Med Welt; 1975 May; 26(20):972-9. PubMed ID: 1094226
    [No Abstract]   [Full Text] [Related]  

  • 10. [Ifosfamide in the treatment of solid tumors and their metastases].
    Wicart L
    Nouv Presse Med; 1976 Apr; 5(15):996-8. PubMed ID: 778786
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of refractory malignant neoplasms with ifosfamide as single agent and in combination chemotherapy.
    Retsas S
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():151-7. PubMed ID: 6627241
    [No Abstract]   [Full Text] [Related]  

  • 12. Ifosfamide: European perspective.
    Burkert H
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):28-35. PubMed ID: 6761866
    [No Abstract]   [Full Text] [Related]  

  • 13. Ifosfamide--pharmacology, safety and therapeutic potential.
    Brade WP; Herdrich K; Varini M
    Cancer Treat Rev; 1985 Mar; 12(1):1-47. PubMed ID: 3896483
    [No Abstract]   [Full Text] [Related]  

  • 14. The place of ifosfamide in chemotherapy of small cell lung cancer: the Eastern Cooperative Oncology Group experience and a selected literature update.
    Ettinger DS
    Semin Oncol; 1995 Feb; 22(1 Suppl 2):23-7. PubMed ID: 7846538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anticancer spectrum of ifosfamide.
    Hunter HL; Harrison EF
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):96-100. PubMed ID: 6761868
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative effects of cyclophosphamide and isophosphamide on Lewis lung carcinoma.
    Corsi A; Calabresi F; Greco C
    Br J Cancer; 1978 Nov; 38(5):631-3. PubMed ID: 728352
    [No Abstract]   [Full Text] [Related]  

  • 17. Ifosfamide as single-agent chemotherapy in inoperable non-small-cell lung cancer.
    Peake MD; Parker D
    Lancet; 1985 Aug; 2(8453):496-7. PubMed ID: 2863510
    [No Abstract]   [Full Text] [Related]  

  • 18. N-acetylcysteine: its bioavailability and interaction with ifosfamide metabolites.
    Morgan LR; Holdiness MR; Gillen LE
    Semin Oncol; 1983 Mar; 10(1 Suppl 1):56-61. PubMed ID: 6836327
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I clinical trial of a 3-day divided dose schedule of ifosfamide (NSC 109724).
    Nelson RL; Creaven PJ; Cohen MH; Fossieck BE
    Eur J Cancer (1965); 1976 Mar; 12(3):195-8. PubMed ID: 780113
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of ifosfamide in germ cell tumors and small cell lung cancer.
    Nichols CR
    Semin Oncol; 1995 Jun; 22(3 Suppl 7):13-7. PubMed ID: 7610394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.